Clinical Trial Update: Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating combination of stereotactic radiosurgery with enhanced immunotherapy for recurrent glioblastoma is in Phase 1/Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• InSituVac2 (InSituVac2)

Snippet

Sponsor: Beijing Tiantan Hospital | Conditions: Recurrent Glioblastoma | Phase 1, Phase 2 | Status: UNKNOWN